Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) Debt-to-Equity : 0.19 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Shandong Weigao Group Medical Polymer Co Debt-to-Equity?

Shandong Weigao Group Medical Polymer Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $360 Mil. Shandong Weigao Group Medical Polymer Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $224 Mil. Shandong Weigao Group Medical Polymer Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,144 Mil. Shandong Weigao Group Medical Polymer Co's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shandong Weigao Group Medical Polymer Co's Debt-to-Equity or its related term are showing as below:

SHWGY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.2 Max: 0.37
Current: 0.19

During the past 13 years, the highest Debt-to-Equity Ratio of Shandong Weigao Group Medical Polymer Co was 0.37. The lowest was 0.03. And the median was 0.20.

SHWGY's Debt-to-Equity is ranked better than
52.74% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs SHWGY: 0.19

Shandong Weigao Group Medical Polymer Co Debt-to-Equity Historical Data

The historical data trend for Shandong Weigao Group Medical Polymer Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Weigao Group Medical Polymer Co Debt-to-Equity Chart

Shandong Weigao Group Medical Polymer Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.34

0.24

0.21

0.19

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.21	0.22	0.21	0.20	0.19

Competitive Comparison of Shandong Weigao Group Medical Polymer Co's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Weigao Group Medical Polymer Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Debt-to-Equity falls into.

Shandong Weigao Group Medical Polymer Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shandong Weigao Group Medical Polymer Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(360.401	+	223.52)	/	3144.047
	=	0.19

Shandong Weigao Group Medical Polymer Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(360.401	+	223.52)	/	3144.047
	=	0.19

Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Shandong Weigao Group Medical Polymer Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shandong Weigao Group Medical Polymer Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shandong Weigao Group Medical Polymer Co Ltd (OTCPK:SHWGY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SHWGF:USA 01066:Hong Kong UK2:Germany

Address

No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN

Website

https://www.weigaogroup.com

Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) Headlines

From GuruFocus

Shandong Weigao Group Medical Polymer Co Ltd's Dividend Analysis

By GuruFocus Research • 10-26-2023

ACell Enters Exclusive Chinese Product Supply and Distribution Agreement for Cytal and MicroMatrix Wound Management Products

By PRNewswire PRNewswire • 04-08-2019